References
- Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003;61:37–49
- Kelleher C, Cardozo LD, Khullar V, Salvatore S. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 1997;104:1374–1379
- National Institute for Health and Clinical Excellence. NICE Clinical Guidance. Urinary incontinence: the management of urinary incontinence in women. London: RCOG Press; 2006
- Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008;54:543–562
- Malhotra B, Gandelman K, Sachse R, et al. The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine. Curr Med Chem 2009;16:4481–4489
- Michel MC. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother 2008;9:1787–1796
- Gani J, Perlis N, Radomski SB. Urologic medications and ophthalmologic side effects: a review. Can Urol Assoc J 2012;6:53–58
- Wong EY, Harding A, Kowal L. Oxybutynin-associated esotropia. J AAPOS 2007;11:624–625
- Altan-Yaycioglu R, Yaycioglu O, Aydin Akova Y, et al. Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial. Br J Clin Pharmacol 2005;59:588–592
- Abrams P, Freeman R, Anderström C, Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998;81:801–810
- Chapple CR, Nilvebrant L. Tolterodine: selectivity for the urinary bladder over the eye (as measured by visual accommodation) in healthy volunteers. Drugs R D 2002;3:75–81
- Sung VC, Corridan PG. Acute-angle closure glaucoma as a side-effect of oxybutynin. Br J Urol 1998;81:634–635
- Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial of extended-release, oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc 2001;76:358–363
- Diokno A, Appell RA, Sand PK, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003;78:687–695
- Sussman D, Garely A. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET). Curr Med Res Opin 2002;18:177–184
- Meeker M, Du R, Bacchetti P, et al. Pupil examination: validity and clinical utility of an automated pupillometer. J Neurosci Nurs 2005;37:34–40
- Feinberg M. The problems of anticholinergic adverse effects in older patients. Drugs Aging 1993;3:335–348
- Chen Z, Li T, Yao P, et al. Effects of 0.05% racanisodamine on pupil size and accommodation. Optom Vis Sci 2010;87:966–970
- Frischmeyer KJ, Miller PE, Bellay Y, et al. Parenteral anticholinergics in dogs with normal and elevated intraocular pressure. Vet Surg 1993;22:230–234
- Ouslander JG, Blaustein J, Connor A, et al. Pharmacokinetics and clinical effects of oxybutynin in geriatric patients. J Urol 1988;140:47–50
- Leung DY, Kwong YY, Lam DS. Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial. Br J Clin Pharmacol 2005;60:668; author reply 669